Literature DB >> 20595682

Reduced hepatic synthesis of calcidiol in uremia.

Josée Michaud1, Judith Naud, Denis Ouimet, Christian Demers, Jean-Luc Petit, Francois A Leblond, Alain Bonnardeaux, Marielle Gascon-Barré, Vincent Pichette.   

Abstract

Calcidiol insufficiency is highly prevalent in chronic kidney disease (CKD), but the reasons for this are incompletely understood. CKD associates with a decrease in liver cytochrome P450 (CYP450) enzymes, and specific CYP450 isoforms mediate vitamin D(3) C-25-hydroxylation, which forms calcidiol. Abnormal levels of parathyroid hormone (PTH), which also modulates liver CYP450, could also contribute to the decrease in liver CYP450 associated with CKD. Here, we evaluated the effects of PTH and uremia on liver CYP450 isoforms involved in calcidiol synthesis in rats. Uremic rats had 52% lower concentrations of serum calcidiol than control rats (P < 0.002). Compared with controls, uremic rats produced 71% less calcidiol and 48% less calcitriol after the administration of vitamin D(3) or 1alpha-hydroxyvitamin D(3), respectively, suggesting impaired C-25-hydroxylation of vitamin D(3). Furthermore, uremia associated with a reduction of liver CYP2C11, 2J3, 3A2, and 27A1. Parathyroidectomy prevented the uremia-associated decreases in calcidiol and liver CYP450 isoforms. In conclusion, these data suggest that uremia decreases calcidiol synthesis secondary to a PTH-mediated reduction in liver CYP450 isoforms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595682      PMCID: PMC3013518          DOI: 10.1681/ASN.2009080815

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  58 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Hepatic oxidative drug metabolism in rats with experimental renal failure.

Authors:  A P Van Peer; F M Belpaire
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-08

3.  Enzyme induction in the uremic liver.

Authors:  H W Leber; L Gleumes; G Schütterle
Journal:  Kidney Int Suppl       Date:  1978-06       Impact factor: 10.545

4.  Downregulation of hepatic cytochrome P450 in chronic renal failure.

Authors:  Francois Leblond; Carl Guévin; Christian Demers; Isabelle Pellerin; Marielle Gascon-Barré; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2001-02       Impact factor: 10.121

5.  Oxidative drug metabolism in liver microsomes from uremic rats.

Authors:  H W Leber; G Schütterle
Journal:  Kidney Int       Date:  1972-09       Impact factor: 10.612

6.  Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.

Authors:  Carl Guévin; Josée Michaud; Judith Naud; Francois A Leblond; Vincent Pichette
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 7.  Eight cytochrome P450s catalyze vitamin D metabolism.

Authors:  Yoshihiko Ohyama; Tomoaki Yamasaki
Journal:  Front Biosci       Date:  2004-09-01

8.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase.

Authors:  Jeffrey B Cheng; Michael A Levine; Norman H Bell; David J Mangelsdorf; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

9.  Identification of a novel rat microsomal vitamin D3 25-hydroxylase.

Authors:  Tomoaki Yamasaki; Shunsuke Izumi; Hiroshi Ide; Yoshihiko Ohyama
Journal:  J Biol Chem       Date:  2004-03-16       Impact factor: 5.157

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  38 in total

1.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

Review 2.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

Review 3.  Effect of nutritional vitamin D preparations on parathyroid hormone in patients with chronic kidney disease.

Authors:  Chrysoula Pipili; Chrysostomos Dimitriadis; Nigar Sekercioglu; Joanne M Bargman; Dimitrios D Oreopoulos
Journal:  Int Urol Nephrol       Date:  2011-08-26       Impact factor: 2.370

4.  Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.

Authors:  Sylvie Dusilová-Sulková; Roman Šafránek; Jaroslava Vávrová; Jiří Horáček; Ladislava Pavlíková; Vladimír Palička
Journal:  Int Urol Nephrol       Date:  2014-09-28       Impact factor: 2.370

5.  Effect of parathyroidectomy on vitamin D levels.

Authors:  Caroline Lamarche; François Leblond; Denis Ouimet; Vincent Pichette
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

6.  Vitamin D and Atherosclerotic Cardiovascular Disease.

Authors:  Thomas Hiemstra; Kenneth Lim; Ravi Thadhani; JoAnn E Manson
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

7.  Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.

Authors:  Sandrine Rauscher; Jean-Philippe Lafrance; Vincent Pichette; Robert Z Bell; Katherine Desforges; Laurence Lepage; Georges Ouellet; Denis Ouimet; Martine Leblanc; Caroline Lamarche; Sarah Bezzaoucha; Michel Vallee
Journal:  Int Urol Nephrol       Date:  2016-11-08       Impact factor: 2.370

Review 8.  Vitamin d deficiency in patients with chronic liver disease and cirrhosis.

Authors:  Lei Yuan Lim; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2012-02

9.  Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD.

Authors:  Jason R Stubbs; Shiqin Zhang; Peter A Friedman; Thomas D Nolin
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-02       Impact factor: 8.237

10.  Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.

Authors:  S Minisola; L Cianferotti; P Biondi; C Cipriani; C Fossi; F Franceschelli; F Giusti; G Leoncini; J Pepe; H A Bischoff-Ferrari; M L Brandi
Journal:  Osteoporos Int       Date:  2017-08-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.